EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors

Xiaoxiao Fan, Chenxi Wei, Minjun Rong, Shengnan Wang, Jiaying Wang, Xiaohan Wang, Xiao Han iD, Xue Meng

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70413 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Xiaoxiao Fan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, B7-H1 Antigen, Lung Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province, Wu Jieping Medical Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PD‐L1 is a reliable biomarker for predicting immunotherapy efficacy in NSCLC patients without driver gene mutations. However, its significance in patients with driver gene‐positive tumors remains unclear. This study analyzed 273 patients with stage IV non‐small cell lung cancer harboring driver gene mutations. All patients had PD‐L1 expression levels ≥10%. The effect of PD‐L1 expression on progression‐free survival (PFS) and overall survival (OS) was assessed. Among the 273 patients with driver gene‐positive NSCLC, 127 had a PD‐L1 tumor proportion score (TPS) of 10–49%, and 146 had TPS ≥50%. Patients in the TPS 10%–49% group had significantly better median PFS and OS compared to those in the TPS ≥50% group ( p = 0.0008 and p = 0.0009, respectively). In the realm of targeted therapy, patients who received first‐line tyrosine kinase inhibitors (TKIs) showed superior outcomes in the TPS 10–49% group compared to the TPS ≥50% group in terms of both median PFS (30.8 months vs. 13.9 months, p = .0001) and OS (44.8 months vs. 26.3 months, p = .0006). Regarding immunotherapy, PD‐L1 expression level was not significantly associated with treatment efficacy. However, in patients with KRAS mutations, those who received first‐line immunotherapy exhibited better median PFS and OS ( p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungB7-H1 AntigenLung NeoplasmsImmune Checkpoint InhibitorsHumansFemaleMaleMiddle AgedAgedMutationAdultAged, 80 and overBiomarkers, TumorOncogenesProtein Kinase InhibitorsProgression-Free SurvivalMolecular Targeted TherapyImmunotherapyPrognosis

Stichwörter der Autor:innen

PD‐L1 expressiondriver gene mutationsimmunotherapynon‐small cell lung cancer (NSCLC)tyrosine kinase inhibitors (TKIs)

Substanzen

B7-H1 AntigenImmune Checkpoint InhibitorsCD274 protein, humanBiomarkers, TumorProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
  • Department of Medical Oncology, Huantai County People's Hospital, Zibo, Shandong, China.
  • Family & Women-Children Health & Family Planning Division, Health and Wellness Service Center (Center for Disease Control and Prevention) of Binzhou Economic and Technological Development Zone, Binzhou, Shandong, China.
  • School of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.

ORCID-Profile: Xiao Han

Förderung

  • Natural Science Foundation of Shandong Province
  • Wu Jieping Medical Foundation
  • National Natural Science Foundation of China
  • CSCO-Nav HER2-related Solid Tumors Research Foundation

Zitieren

APA

Fan, X., Wei, C., Rong, M., Wang, S., Wang, J., Wang, X., Han, X., & Meng, X. (2026). Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors. International Journal of Cancer. https://doi.org/10.1002/ijc.70413

Vancouver

Fan X, Wei C, Rong M, Wang S, Wang J, Wang X, et al. Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors. International Journal of Cancer. 2026. doi:10.1002/ijc.70413

BibTeX
@article{Fan2026,
  author = {Fan, Xiaoxiao and Wei, Chenxi and Rong, Minjun and Wang, Shengnan and Wang, Jiaying and Wang, Xiaohan and Han, Xiao and Meng, Xue},
  title = {Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70413}
}
Kostenlos starten →